Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- Innovative Approach to Fumed Silica Production by PyroGenesis
- NMD Pharma Showcases Breakthrough Research in Myasthenia Gravis
- Revolutionizing Pet Care: The AI-Powered Future of Pet Health
- Celebrating AANHPI Heritage Month: Sabio's Commitment to Diversity
- Discovering the Impact of the Blockchain Futurist Conference
- Exciting New Campaign by Keeper Security Featuring Carlos Sainz
- Understanding Recent Transactions by Anne-Maria Salonius at Ålandsbanken
- Leap Therapeutics Shares Promising Financial Update and Progress
- Cellectar Biosciences Highlights Q1 2025 Growth and Plans
- Revolutionizing Nutraceuticals: The SUANNUTRA & Myota Alliance
- Y-mAbs Prepares for Significant R&D Update on Radiopharmaceuticals
- RedHill Biopharma Achieves Legal Victory Over Kukbo Holdings
- Discover the Enhanced 2026 Toyota bZ All Electric SUV Features
- Immatics Reveals First Quarter 2025 Financial Performance and Updates
- Adam Bates Joins XION to Revolutionize Blockchain Marketing
- Regula Established as a Leader in Biometric Age Verification Tech
- United Airlines Elevates International Travel Experience
- Discover the Premier Crypto Casino Experience in Canada
- Revolutionizing Enterprise Data Management with AI-Ready Solutions
- Air Coolers Market Forecast: Surging Demand and Growth Trends
- Reshift Media Partners with Ripley PR to Elevate Visibility
- Veriff Recognized as a Leading Identity Verification Solution
- Acurx Pharmaceuticals Advances with Robust Q1 Financials
- Exploring Skye Bioscience's Breakthrough for Effective Weight Loss
- New Primate Ownership Legislation Promoted by Congressman Quigley
- Algernon Pharmaceuticals Expands with Acquisition of NoBrainer Imaging Centers
- Mount Franklin Foods Launches Unique Gummy Candy Innovation
- Empowering Gen Z: The Future of Skilled Trades Careers
- Aya Gold & Silver Achieves Record Production and Growth Momentum
- Silicon Labs Delivers Impressive Q1 2025 Financial Highlights
- Coda Octopus Group Secures $1.5m Order for Innovative DAVD Systems
- Exciting Breakthrough for REGENXBIO: RGX-121 Review Update
- Axsome Therapeutics Secures $570 Million Credit Facility Boost
- Boosting Vacation Rentals: PetScreening Teams with OwnerRez
- Microbix and Aurevia Launch Groundbreaking EQA Program for BV
- Revolutionary Cell Analyzer Unveiled for Scientific Community
- Aduro Clean Technologies Partners with Generation IACP for Growth
- Nuwellis, Inc. Achieves Growth in First Quarter Financial Results
- G2 Goldfields Unveils Promising Drilling Results at Peters Mine
- Broadwind's Q1 2025 Performance: Insights and Financial Overview
- Legend Biotech Posts Impressive Q1 Results with CARVYKTI Growth
- Bilibili Inc. Invites 1.25% Convertible Noteholders for Repurchase
- Instil Bio's Q1 2025 Financial Results: Key Insights and Updates
- atai Life Sciences Advances Mental Health Treatment with EMP-01
- Editas Medicine Showcases Remarkable Gene Editing Advances in Liver Research
- Invivyd Management Engages Investors at BioConnect Conference
- Rogers Sugar Reports Strong Q2 Performance Amid Market Changes
- Rogers Sugar Inc. Announces New Quarterly Dividend Payment
- Revolutionary Study Shows Titan SGS™ Stapler Reduces GERD
- Insights into Nykredit Realkredit A/S Key Transactions